OptiBiotix Health plc (AIM: OPTI) reported strong revenue and margin growth in its audited results for 2025 as the company continued expanding international sales of its weight management and gut

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes,

OptiBiotix Health plc (AIM: OPTI), a life sciences company focused on products that reduce hunger and food cravings, improve the gut microbiome, and offer sweet fibres as healthy sugar alternatives,

New SlimBiome® study published in European Journal of Nutrition

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, provides the

Launch of Daily Nouri FeelFull product in America SlimBiome® containing finished products

OptiBiotix Health plc (AIM: OPTI) (“OptiBiotix”) the life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, advises that in relation to the requisitioned general meeting of

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces further positive study results.